Webinar : The Ultimate Cleaning Validation Blueprint · Aug 27 · 10 AM EST Save Your Seat
Experience Leucine AI .
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Laboratory Controls
Laboratory Controls
View Detailed Analysis

Analytics Overview

85
Form 483s Issued
23
483s converted to WL
112
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
18 Jul 2025
Dr. Reddy's Laboratories Limited , FTO-11
Drugs
18 Jul 2025
GenoGenix, LLC
Drugs
11 Jul 2025
Center for Drug Evaluation and Research
Drugs
10 Apr 2025
Aurolige Pharma LLC
Drugs
24 Jan 2025
Turbare Manufacturing
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
19
8
Anastasia M Shields
10
4
Jose E Melendez
8
2
Crystal Monroy
7
0
Patty P Kaewussdangkul
6
3
TITLE/ COMPANY Issue Date Status Details
Drug product production and control records, are not reviewed and approved by the quality control unit
Dr. Reddy's Laboratories Limited , FTO-11
18 Jul 2025 Normal Justification: The observation highlights issues in laboratory operations, specifically neglect in proper documentation of microbial data.
Excerpt: The supervisor failed to document the readings during the secondary verification despite LIMS having the capability.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that components, closures, in-process materials and drug products conform to appropriate standards
GenoGenix, LLC
18 Jul 2025 Normal Justification: Laboratory Controls are linked to the observation due to the failure in establishing appropriate specifications and testing procedures as noted in the observation.
Excerpt: Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures
Center for Drug Evaluation and Research
11 Jul 2025 Normal Justification: Laboratory Controls are directly responsible for ensuring that sampling plans are scientifically sound to validate product quality.
Excerpt: Firm lacks a scientifically sound sampling plan for the Powdered Aluminum Hydroxide testing.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
Aurolige Pharma LLC
10 Apr 2025 Normal Justification: Laboratory control weaknesses manifest in the method implementation and criteria adjustments without proper rigour.
Excerpt: Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform.
View Details
Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for accuracy, completeness and compliance with established standards
Turbare Manufacturing
24 Jan 2025 Normal Justification: Laboratory controls ensure data integrity, accuracy, and review compliance. Lack of second review violates these principles, impacting regulatory adherence.
Excerpt: Your firm does not require a second reviewer for environmental monitoring results unless colony forming unit (CFU) is found.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Laboratory Controls

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Written By
Vivek Gera
Reading Time
8
Minutes

Laboratory Controls

Overview

85
Form 483s Issued
23
483s converted to WL
112
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
18 Jul 2025
Dr. Reddy's Laboratories Limited , FTO-11
Drugs
18 Jul 2025
GenoGenix, LLC
Drugs
11 Jul 2025
Center for Drug Evaluation and Research
Drugs
10 Apr 2025
Aurolige Pharma LLC
Drugs
24 Jan 2025
Turbare Manufacturing
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
19
8
Anastasia M Shields
10
4
Jose E Melendez
8
2
Crystal Monroy
7
0
Patty P Kaewussdangkul
6
3

Key Observations

TITLE/ COMPANY Issue Date Status Details
Drug product production and control records, are not reviewed and approved by the quality control unit
Dr. Reddy's Laboratories Limited , FTO-11
18 Jul 2025 Normal Justification: The observation highlights issues in laboratory operations, specifically neglect in proper documentation of microbial data.
Excerpt: The supervisor failed to document the readings during the secondary verification despite LIMS having the capability.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that components, closures, in-process materials and drug products conform to appropriate standards
GenoGenix, LLC
18 Jul 2025 Normal Justification: Laboratory Controls are linked to the observation due to the failure in establishing appropriate specifications and testing procedures as noted in the observation.
Excerpt: Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures
Center for Drug Evaluation and Research
11 Jul 2025 Normal Justification: Laboratory Controls are directly responsible for ensuring that sampling plans are scientifically sound to validate product quality.
Excerpt: Firm lacks a scientifically sound sampling plan for the Powdered Aluminum Hydroxide testing.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
Aurolige Pharma LLC
10 Apr 2025 Normal Justification: Laboratory control weaknesses manifest in the method implementation and criteria adjustments without proper rigour.
Excerpt: Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform.
View Details
Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for accuracy, completeness and compliance with established standards
Turbare Manufacturing
24 Jan 2025 Normal Justification: Laboratory controls ensure data integrity, accuracy, and review compliance. Lack of second review violates these principles, impacting regulatory adherence.
Excerpt: Your firm does not require a second reviewer for environmental monitoring results unless colony forming unit (CFU) is found.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources